Sign in

    Kripa Devrakonda • Truist Securities

    Srikripa Devarakonda is a Vice President and Equity Research Analyst at Truist Securities specializing in biotechnology and healthcare sector coverage. Devarakonda covers companies such as Kymera Therapeutics, Cytokinetics, Scholar Rock Holding, Regeneron Pharmaceuticals, and Edgewise Therapeutics, and has issued over 340 stock ratings, with approximately 89% rated Buy and a documented best recommendation achieving a 187% return for Kymera Therapeutics. Since joining Truist in the early 2020s, Devarakonda has established a research record recognized by platforms like TipRanks and Anachart, with a career success rate of about 37% and an average return of -2.8%, following previous experience in scientific and analytical roles. Devarakonda holds professional securities licenses including FINRA Series 7, 63, and 86/87, supporting comprehensive equity and financial analysis in the U.S. healthcare sector.

    Kripa Devrakonda's questions to Kyverna Therapeutics Inc (KYTX) leadership

    Kripa Devrakonda's questions to Kyverna Therapeutics Inc (KYTX) leadership • Q2 2024

    Question

    Kripa Devrakonda from Truist asked how Sanofi's separate collaboration on a STAT6 degrader might impact Chimera's IRAC4 partnership, and also asked if the KT474 dose expansion was discussed with the FDA.

    Answer

    CEO Nello Manalfi stated that Sanofi's interest in STAT6 validates the target's importance and does not expect it to impact their strong, independent IRAC4 collaboration. Regarding the FDA, he could not comment on specific regulatory discussions, noting that Sanofi, as the trial sponsor, is responsible for that communication.

    Ask Fintool Equity Research AI